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S166 Oral PresentationsGVL. We report a completed phase I/II study of bortezomib-based
GVHD prophylaxis in 1-2 locus HLA-mismatched (A, B, C, DRB1,
DQB1) unrelated donor (MMUD) RIC HSCT. Phase I data docu-
mentedMTDand safety of a regimen of bortezomib (1.3mg/m2; day
11, 14, 17), methotrexate and tacrolimus.
Patients: 45 patients with a median age of 59 years (range, 27-72)
were enrolled. Donor mismatch: HLA-A (12), B (10), C (14),
DRB1 (2), DQB1 (2), B1C (4), DRB11DQB1 (1); 1-antigen (28),
2-antigen (3), 1-allele (11), 2-allele (1), 1-antigen11-allele (2). Dis-
ease: AML (14), NHL (11), CLL/PLL (8), HD (4), MDS (4), ALL
(2), MPD (2). 8 had prior transplants. Median follow-up in survivors
was 12.5 months (range, 3.3-37.2).
Results: Median time to PMN and platelet engraftment was 13
(range, 6-29) and 20 days (range, 13-27) respectively; notably 23 pa-
tients had no PMN nadir and 21 had no platelet nadir. 1 patient failed
to engraft and 4 did not sustain graft chimerism $ 70% through day
1100 in the absence of disease relapse/progression. Median day 130
and 1100 chimerism was 97% and 99% respectively. 15 patients re-
lapsed. 9 patients died: relapse-6; bacterial infection-2; CNS hemor-
rhage-1. 11 had grade 2-4 acute GVHD (gr-2:8; gr-3:3). 16 had
chronic GVHD requiring systemic therapy. No neuropathy flare or
colonic necrosis was noted. Adjusted for competing risks, 6-month
cumulative incidence of grade 2-4 acute GVHD is 24% (95% CI,
13-38); and 1-year cumulative incidence of NRM is 7% (95% CI,
2-18), relapse is 32% (95% CI, 18-47), and chronic GVHD is 39%
(95% CI, 23-55). 1-year progression-free survival is 61% (95% CI,
44-74), and overall survival is 77% (95% CI, 60-87). Preliminary
data suggest improved T-cell reconstitution with this regimen.
Conclusion: Bortezomib-based therapy enabled GVHD control af-
ter MMUD HSCT without impaired immunologic reconstitution,
relapse, orNRM. 1-year survival is encouraging. Proteasome-inhibi-
tion should be evaluated in a randomized GVHD prevention trial.39
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In a large retrospective analysis of outcomes among 567 recipients
of HLA-identical hematopoietic cell transplantation (HCT), we
found that prior treatment of donors with statins, a class of drugs
with cholesterol-lowering and immune-modulating effects, was asso-
ciated with profound protection against severe acute GVHD (Rotta et
al., Blood. 2010;115:1288). The protective effect was restricted to re-
cipients given cyclosporine (CSP)-based postgrafting immunosup-
pression and not observed among those given tacrolimus (TAC).
Based on the unexpected effect-association between statins and
CSP, we hypothesized that CSP and statins synergize in inducing
T cell hyporesponsiveness at the level of the mitochondrial mem-
brane by interacting with a number of cyclophilins, including cyclo-
philin D. To mimic the clinical HCT setting where donors are
treated with statins and recipients are given immunosuppressive
therapy with either CSP orTAC, wemeasured the bioenergeticmet-
abolic status (mitochondrial function) of T cells obtained from dogs
that were treated with statins in vivo as a function of activation ex vivo
in the presence of CSP or TAC. Specifically, dogs (n 5 3) were
treated with atorvastatin (2 mg/kg/day) and, after 3 weeks of statin
treatment, peripheral blood T cells were purified and activated
with concanavalin A (conA) in the presence of suboptimal concentra-
tions of either CSP (30 ng/mL) or TAC (0.1 ng/mL). Mitochondrial
function was then evaluated by serial real-time measurements of the
oxygen consumption rate (OCR) as an indicator of oxidative phos-
phorylation by using the Seahorse XF24 Extracellular Flux Analyzer.
In the presence of CSP, T cells from dogs treated in vivowith ator-
vastatin (n 5 3), total oxygen consumption during the first 5 hours
after conA-activation was reduced by 41% (p 5 0.12), 70% (p 5
0.005) and 100% (p 5 0.008), respectively, compared to T cells ac-
tivated in the absence of CSP. This statin-induced reduction inOCR
was not observed when in vivo statin-exposed T cells were activated
in the presence of TAC. Neither CSP nor TAC significantly sup-
pressed OCR in control T cells obtained from dogs that were nottreated with atorvastatin (n5 3). In summary, these findings support
our hypothesis that statins and CSP have synergistic inhibitory ef-
fects onmitochondrial function in activatedT cells, and they provide
a first step toward defining the key mechanisms of statin-mediated
protection against GVHD.40
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Chronic graft-versus-host disease (cGVHD) remains a major cause
of late death and morbidity after allogeneic hematopoietic cell trans-
plantation, and the treatment of cGVHD remains challenging. To in-
vestigate the roles of Th17 cells and other Th subsets (Th1 and Th2)
in cGVHD, we first assessed the kinetics of Th cytokines in the
B10.D2 (H-2d)/ BALB/c (H-2d) model of cGVHD. In the early
phase (day 14) of post bone marrow transplant (BMT), donor T cells
produced significantly less IL-17 in the peripheral lymph nodes
(PLNs) of recipients in allogeneic BMT than in syngeneic BMT
(1.6860.09% vs. 4.3060.53%, p \ 0.01), while in the late phase
(day 28) donor T cells that produced IL-17 were increased signifi-
cantly in allogeneic recipients, compared with syngeneic controls
(7.7660.27% vs. 1.6160.16%, p\ 0.005). Next, we evaluated the
role of Th17 on cGVHD using IL-17-deficient mice on a B10.D2
background as donor mice. Upon transfer of IL-172/2 donor T cells,
skin cGVHDwas significantly ameliorated, as compared to recipients
of wild-type (WT) T cells (p 5 0.02). Histopathological examination
of the skin showed significantly reduced cGVHD pathology in recip-
ients of IL-172/2 donors (3.1761.09 vs. 8.5060.84, p5 0.006). Flow
cytometry analysis of the PLNs in the early phase (day 14) showed no
differences in Th1, Th2, and Tregs, while recipients of IL-172/2 had
significantly fewer Th1 (p\ 0.05) and Th17/Th1 (p\ 0.01) cells on
day 35. Furthermore, BMT from IFN-g2/2 B10.D2 donors signifi-
cantly improved the clinical cGVHD score, compared with WT do-
nors (p \ 0.05). Interestingly, in the early phase (day 14) of post
BMT, IFN-g2/2 donor T cells produced significantly more IL-17
in the PLNs than WT donor (4.4260.65% vs. 1.7160.27%, p \
0.01), while in the late phase (day 35), IFN-g2/2 donor T cells that
produced IL-17were decreased. Finally, we demonstrated that the ad-
ministration of ATRA or Am80, significantly decreased skin fibrosis
and alopecia, a dominant feature of cutaneous cGVHD. Flow cytom-
etry analysis of the PLNs on day 16 showed significant reductions in
Th1 and Th17 in Am80-treated recipients, as compared to controls.
Taken together, Th17, especially in the late-chronic phase, and Th1
contribute to the development of cGVHD by promoting the produc-
tion of proinflammatory cytokines. Targeting Th17 and Th1 may be
a promising strategy for preventing and treating cGVHD.41
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Background: Direct intrabone (IB) transplantation has been sug-
gested as a method to improve hematopoietic engraftment. An addi-
tional benefit may be an abrogation of graft versus host disease
(GVHD). In mouse models, IB injection of allogeneic splenocytes
prevents murine GVHD attributable to the immunosuppressive ef-
fect of the bone marrow stromal environment. The NSG mouse
